Rxcel

RXcel is a Swiss pre-seed biotech company developing Smart RNA therapeutics to treat patients with aggressive cancers. Our mission is to identify clinical biomarkers from patient tissues and to develop a pipeline of RNA-based therapeutic candidates. Our novel Smart RNA therapeutics are designed to ensure specific targeting of cancer cells and enable patient safety through innovative delivery systems. At RXcel, we are now assembling a world-class team of scientific, clinician, and strategic experts—and we are looking for investors who share our vision. Together, we aim to transform cancer care by delivering smarter, safer RNA therapeutics that improve patient outcomes.